Molibresib (I-BET-762)

For research use only. Not for use in humans.

目录号：S7189 别名： GSK525762, GSK525762A

Molibresib (I-BET-762) Chemical Structure

CAS No. 1260907-17-2

Molibresib (I-BET-762, GSK525762, GSK525762A) 是一种BET蛋白抑制剂，无细胞试验中IC50约为35 nM，抑制巨噬细胞产生促炎性蛋白质，并抑制急性炎症，对其他溴区结合域包含的蛋白具有高度选择性。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 2923.83	现货
2mg	RMB 1859.99	现货
10mg	RMB 3838.64	现货
50mg	RMB 9582.91	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Molibresib (I-BET-762)发表文献21篇：

Cancer Discov, 2018, 8(4):458-477

PubMed: 29386193 ( click the link to review the publication )

Cancer Cell, 2017, 31(5):635-652

PubMed: 28434841 ( click the link to review the publication )

Acta Neuropathol, 2021, 10.1007/s00401-021-02341-z

PubMed: 34283254 ( click the link to review the publication )

Cell Chem Biol, 2021, S2451-9456(21)00400-1

PubMed: 34525344 ( click the link to review the publication )

Commun Biol, 2021, 4(1):878

PubMed: 34267311 ( click the link to review the publication )

Nat Commun, 2020, 14;11(1):1833

PubMed: 32286255 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 4;5(1):20

PubMed: 32296021 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(10):9240-9259

PubMed: 32392533 ( click the link to review the publication )

Cancer Sci, 2020, 112(1):133-143

PubMed: 33067904 ( click the link to review the publication )

J Hematol Oncol, 2019, 12(1):73

PubMed: 31288832 ( click the link to review the publication )

EBioMedicine, 2019, 43:201-210

PubMed: 30975544 ( click the link to review the publication )

Am J Transl Res, 2019, 11(2):1030-1039

PubMed: 30899402 ( click the link to review the publication )

Leuk Res, 2019, 77:42-50

PubMed: 30642575 ( click the link to review the publication )

Mol Cell, 2018, 71(4):592-605

PubMed: 30057199 ( click the link to review the publication )

Cancer Res, 2018, 78(15):4331-4343

PubMed: 29792310 ( click the link to review the publication )

Cancer Res, 2018, 78(20):5731-5740

PubMed: 30135193 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2796-2810

PubMed: 30242092 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(2):285-299

PubMed: 27980108 ( click the link to review the publication )

Cancer Discov, 2016, 6(6):612-29

PubMed: 27099234 ( click the link to review the publication )

Nature, 2016, 534(7607):407-411

PubMed: 27281208 ( click the link to review the publication )

Oncotarget, 2016, 7(24):35753-35767

PubMed: 26840085 ( click the link to review the publication )

产品安全说明书

Epigenetic Reader Domain抑制剂选择性比较

生物活性

产品描述

靶点

BET proteins ^[1]
(Cell-free assay)

35 nM

体外研究

I-BET-762抑制BET(溴区和额外的末端结构域) 蛋白, BRD2, BRD3 和 BRD4, 结合到BET的串联溴区，K_d为50.5-61.3 nM, 在FRET分析中，置换BET串联溴区的一种四乙酰化的H4肽，IC50为32.5-42.5 nM。I-BET-762占据BET蛋白的乙酰基-赖氨酸结合口袋，并抑制BET蛋白结合到乙酰化的组蛋白，从而破坏了炎性基因表达必不可少的染色质复合物的形成。^[1]分化过程中的第2天使用I-BET-762处理，改变CD4⁺T细胞的细胞因子产生，上调一些抗炎基因产物的表达，并下调一些促炎细胞因子的表达。^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
HepG2	MWLGeY5kfGmxbjDhd5NigQ>?		M1e1OVE5KGi{cx?=	NWjoNpp6UW6mdXP0bY9vKG:oIHj1cYFvKEGyb1GxJIdmdmViZYjwdoV{e2mxbjDpckB{fGGkbImgeJJidnOoZXP0[YQhcHWvYX6gTIVxTzJiY3XscJMh[2:neIDy[ZN{cW6pIHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjZoTldkAyQCCqcoOgZpkhdHWvaX7ld4NmdmOnIHHzd4F6NCCHQ{WwJF0hOC55IN88UU4>	M1LhS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNU[4N\|IzLz5{MUW2PFMzOjxxYU6=
HepG2	Mn7QSpVv[3Srb36gZZN{[Xl?		MoPTOkBpenN?	M{K4Omlv\HWldHnvckBw\iCqdX3hckBCeG:DMTDwdo91\WmwIIP5cpRp\XOrczDpckBpfW2jbjDI[ZBIOiClZXzsd{Bie3Onc4Pl[EBieyCwZX;zfY51cGW\|aYPl[EBz[WSrb3zhZoVt\WRicILveIVqdiC\|ZXPy[ZRqd25iYX\0[ZIhPiCqcoOgZpkhW0SVIGDBS2Uh[W6jbInzbZMhcW5icILld4Vv[2Vib3[gX\|M2W12vZYTobY9vcW6n	M4jCOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNU[4N\|IzLz5{MUW2PFMzOjxxYU6=
HepG2	M3fHVGZ2dmO2aX;uJIF{e2G7		NUnm[YZPOThiaILz	NFTzN3FWeHKnZ4XsZZRqd25ib3[gRZBwSTFiZYjwdoV{e2mxbjDpckBpfW2jbjDI[ZBIOiClZXzsd{Bie3Onc4Pl[EBieyClb37j[Y51emG2aX;uJJJmeXWrcnXkJJRwKGmwY4LlZZNmKDdyJTDv[kBtfWOrZnXyZZNmKGGldHn2bZR6KGGodHXyJFE5KGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFXDNVcxKD1iMD6yJO69VS5?	NULTeplvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzPFY2OjlpPkKyN\|g3PTJ7PD;hQi=>
HepG2	NWHaS3BqTnWwY4Tpc44h[XO\|YYm=		NHPmPZkyQCCqcoO=	MljmTY5lfWO2aX;uJI9nKGi3bXHuJGFxd0FzIHflcoUh\XiycnXzd4lwdiCrbjDzeIFjdHlidILhcpNn\WO2ZXSgbJVu[W5iSHXwS\|Ih[2WubIOgZ49mgHC{ZYPzbY5oKGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBi\nSncjCxPEBpenNiYomgcJVucW6nc3PlcoNmKGG\|c3H5MEBGSzVyIE2gNE44KM7:TT6=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjl{NESzOEc,OjJ7MkS0N\|Q9N2F-
PBMC	Ml24RY51cWmwZnzhcY1ifG:{eTDhd5NigQ>?			M{\5PGFvfGmrbn\sZY1u[XSxcomgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCSQl3DJINmdGy\|IHHzd4V{e2WmIHHzJGxRWy2rbnT1Z4VlKEmOLU[gdJJw\HWldHnvckBjgSClaHXtbYx2dWmwZYPj[Y5k\SCjc4PhfUwhUUN3MDC9JFAvOzF4MkOg{txONg>?	NFPNSpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECxOVk3Pyd-MkSwNVU6Pjd:L3G+
Raji	MlfvSpVv[3Srb36gZZN{[Xl?		NFvNNmY1KGi{cx?=	Mme2TY5pcWKrdHnvckBw\iCEUlS0JIlvKGi3bXHuJHJicmliY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIH;mJG1[SyCneIDy[ZN{cW:wIHHmeIVzKDRiaILzMEBKSzVyIE2gNE4yQSEQvF2u	NV3pW2pTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA4PThpPkK0PVAxPzV6PD;hQi=>
Rosetta2 DE3	M4fUXGZ2dmO2aX;uJIF{e2G7		MmfJN\|AhdWmwcx?=	MlLHSIl{eGyjY3Xt[Y51KG:oIF\BUU1t[WKnbHXkJHpDSTJ2ODDmdo9uKEKUREOgRmQzKCh\|ME[geI8hPDF5IHHtbY5wKGGlaXSgdoV{cWS3ZYOpJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKFKxc3X0eIEzKESHMzDj[YxteyCjZoTldkA{OCCvaX7zJIJ6KG[udX;y[ZNk\W6lZTDwc4xiemm8YYTpc44h[XO\|YYmsJGtqKD1iMD6wN\|A{KM7:TT6=	NHzkPGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC4NFA3PCd-Mk[wPFAxPjR:L3G+
Rosetta2 DE3	MUPGeY5kfGmxbjDhd5NigQ>?		M{joSlMxKG2rboO=	NYLGWlRnTGm\|cHzhZ4Vu\W62IH;mJGZCVS2uYXLlcIVlKFqEQUK0PEBnem:vIFLSSFQhSkR{IDizN\|MhfG9iNE[wJIFucW6xIHHjbYQhemW\|aXT1[ZMqKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIGLvd4V1fGF{IFTFN{Bk\WyuczDh[pRmeiB\|MDDtbY5{KGK7IH\seY9z\XOlZX7j[UBxd2yjcnn6ZZRqd25iYYPzZZktKEurIE2gNE4xOzJ\|IN88UU4>	NFn1[5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC4NFA3PCd-Mk[wPFAxPjR:L3G+
Rosetta2 DE3	MlW1SpVv[3Srb36gZZN{[Xl?		M125U\|MxKG2rboO=	NGPBNFZFcXOybHHj[Y1mdnRib3[gSmFONWyjYnXs[YQhYkKDMkS4JIZzd21iQmLEOEBDTDFiKES0JJRwKDF4ODDhcYlvdyCjY3nkJJJme2mmdXXzLUApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCUb4PleJRiOiCGRUOgZ4VtdHNiYX\0[ZIhOzBibXnud{BjgSCobIXvdoV{[2WwY3WgdI9t[XKrenH0bY9vKGG\|c3H5MEBMcSB;IECuNFM5QCEQvF2u	NHG2bHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC4NFA3PCd-Mk[wPFAxPjR:L3G+
Rosetta2 DE3	M4TqTWZ2dmO2aX;uJIF{e2G7			MkOxRolv\GmwZzDh[oZqdmm2eTD0c{BjcW:2aX75cIF1\WRiQmLEN{BDTDJiKEOwOkB1dyB2MUegZY1qdm9iYXPp[EBz\XOrZIXld{khMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iUn;z[ZR1[TJiRFWzJINmdGy\|IHL5JIJqdy2uYYnldkBqdnSncn\ldo9u\XS{eTDt[ZRpd2RuIFvkJF0hOC5yNEC3JO69VS5?	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB6MEC2OEc,OjZyOECwOlQ9N2F-
Rosetta2 DE3	MmfaSpVv[3Srb36gZZN{[Xl?			NVvmeWR5SmmwZHnu[{Bi\m[rbnn0fUB1dyCkaX;0bY56dGG2ZXSgRnJFOiCEREKgLFM1QSC2bzC0OlAh[W2rbn:gZYNq\CC{ZYPp[JVmeyliKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gVo9{\XS2YUKgSGU{KGOnbHzzJIJ6KGKrbz3sZZlmeiCrboTldoZmem:vZYTyfUBu\XSqb3SsJGtlKD1iMD6wOFU1KM7:TT6=	MmrZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOECwOlQoRjJ4MEiwNFY1RC:jPh?=
Rosetta2 DE3	M1PCc2Z2dmO2aX;uJIF{e2G7			NVHWOGtISmmwZHnu[{Bi\m[rbnn0fUB1dyCkaX;0bY56dGG2ZXSgRnJFPCCEREKgLFM{OyC2bzC0OlAh[W2rbn:gZYNq\CC{ZYPp[JVmeyliKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gVo9{\XS2YUKgSGU{KGOnbHzzJIJ6KGKrbz3sZZlmeiCrboTldoZmem:vZYTyfUBu\XSqb3SsJGtlKD1iMD6wOFc3KM7:TT6=	M4fUcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEiwNFY1Lz5{NkC4NFA3PDxxYU6=
Rosetta2 DE3	M4nJU2Z2dmO2aX;uJIF{e2G7		NVK2OZZ6OzBibXnudy=>	NF\tdYtFcXOybHHj[Y1mdnRib3[gSmFONWyjYnXs[YQhYkKDMkS4JIZzd21iQmLENkBDTDJiKEO0PUB1dyB2NkCgZY1qdm9iYXPp[EBz\XOrZIXld{khMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iUn;z[ZR1[TJiRFWzJINmdGy\|IHHmeIVzKDNyIH3pcpMh[nliZnz1c5Jme2OnbnPlJJBwdGG{aYrheIlwdiCjc4PhfUwhU2liPTCwMlA1QTJizszNMi=>	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB6MEC2OEc,OjZyOECwOlQ9N2F-
Rosetta2 DE3	MnnNSpVv[3Srb36gZZN{[Xl?		NU\l[IlIOzBibXnudy=>	MYrEbZNxdGGlZX3lcpQhd2ZiRlHNMYxi[mWuZXSgXmJCOjR6IH\yc40hSlKGMzDCSFEhMDJ2IITvJFE1PCCjbXnuc{Bi[2mmIILld4llfWW\|KTCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBTd3OndIThNkBFTTNiY3XscJMh[W[2ZYKgN\|AhdWmwczDifUBndHWxcnXzZ4Vv[2VicH;sZZJqgmG2aX;uJIF{e2G7LDDLbUA:KDBwMEWzPUDPxE1w	MkPsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOECwOlQoRjJ4MEiwNFY1RC:jPh?=
Rosetta2 DE3	MXrGeY5kfGmxbjDhd5NigQ>?		NEXUcng{OCCvaX7z	M2Pm[WRqe3CuYXPlcYVvfCCxZjDGRW0udGGkZXzl[EBbSkF{NEig[pJwdSCEUlSyJGJFOSBqN{KgeI8hOjB3IHHtbY5wKGGlaXSgdoV{cWS3ZYOpJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKFKxc3X0eIEzKESHMzDj[YxteyCjZoTldkA{OCCvaX7zJIJ6KG[udX;y[ZNk\W6lZTDwc4xiemm8YYTpc44h[XO\|YYmsJGtqKD1iMD6wOVY5KM7:TT6=	MnTrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOECwOlQoRjJ4MEiwNFY1RC:jPh?=
Rosetta2 DE3	MlHtSpVv[3Srb36gZZN{[Xl?			MXvCbY5lcW6pIHHm[olvcXS7IITvJIJqd3SrbonsZZRm\CCEUlSzJGJFOSBqMkSgeI8hOTR2IHHtbY5wKGGlaXSgdoV{cWS3ZYOpJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKFKxc3X0eIEzKESHMzDj[YxteyCkeTDibY8udGG7ZYKgbY51\XKoZYLvcYV1enlibXX0bI9lNCCNZDC9JFAvODZyNzFOwG0v	NFnHTno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC4NFA3PCd-Mk[wPFAxPjR:L3G+
MV4-11	M1HndGN6fG:2b4jpZ4l1gSCjc4PhfS=>		M{DoVlQh\GG7cx?=	NHjWSnNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOXjRvMUGgZ4VtdHNiaHHyZo9zcW6pIF3MUFEh\nW\|aX;uJIdmdmViYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiNDDkZZl{KGK7IFPlcIxVcXSncj3HcI8hdHWvaX7ld4NmdnRiYYPzZZktKEmFNUCgQUAxNjB7MzFOwG0v	NUWyWmJuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPFAxPjRpPkK2NFgxODZ2PD;hQi=>
Rosetta2 DE3	NFfFRWRHfW6ldHnvckBie3OjeR?=		NEHTNnQ{OCCvaX7z	NH;oRnZFcXOybHHj[Y1mdnRib3[gSmFONWyjYnXs[YQhYkKDMkS4JIZzd21iQmLEOEBDTDJiKEOzN{B1dyB2NkCgZY1qdm9iYXPp[EBz\XOrZIXld{khMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iUn;z[ZR1[TJiRFWzJINmdGy\|IHHmeIVzKDNyIH3pcpMh[nliZnz1c5Jme2OnbnPlJJBwdGG{aYrheIlwdiCjc4PhfUwhUUN3MDC9JFAvODl6NDFOwG0v	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB6MEC2OEc,OjZyOECwOlQ9N2F-
Rosetta2 DE3	NF;Bc4RHfW6ldHnvckBie3OjeR?=			M4rNeGJqdmSrbnegZYZncW6rdImgeI8h[mmxdHnufYxifGWmIFLSSFQhSkRzIDi0OEB1dyBzNkigZY1qdm9iYXPp[EBz\XOrZIXld{khMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iUn;z[ZR1[TJiRFWzJINmdGy\|IHL5JIJqdy2uYYnldkBqdnSncn\ldo9u\XS{eTDt[ZRpd2RuIFvkJF0hOC5yOUm0JO69VS5?	NXvJephCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPFAxPjRpPkK2NFgxODZ2PD;hQi=>
Rosetta2 DE3	MYPGeY5kfGmxbjDhd5NigQ>?		NFSxRVk{OCCvaX7z	MUDEbZNxdGGlZX3lcpQhd2ZiRlHNMYxi[mWuZXSgXmJCOjR6IH\yc40hSlKGNDDCSFEhMDR2IITvJFE3QCCjbXnuc{Bi[2mmIILld4llfWW\|KTCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBTd3OndIThNkBFTTNiY3XscJMh[W[2ZYKgN\|AhdWmwczDifUBndHWxcnXzZ4Vv[2VicH;sZZJqgmG2aX;uJIF{e2G7LDDJR\|UxKD1iMD6xOVYh\|ryPLh?=	M3P1XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEiwNFY1Lz5{NkC4NFA3PDxxYU6=
Rosetta2 DE3	M2jL[GZ2dmO2aX;uJIF{e2G7			M4KweGJqdmSrbnegZYZncW6rdImgeI8h[mmxdHnufYxifGWmIFLSSFIhSkRzIDi3NkB1dyB{MEWgZY1qdm9iYXPp[EBz\XOrZIXld{khMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iUn;z[ZR1[TJiRFWzJINmdGy\|IHL5JIJqdy2uYYnldkBqdnSncn\ldo9u\XS{eTDt[ZRpd2RuIFvkJF0hOC5zNUmg{txONg>?	NF\1T2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC4NFA3PCd-Mk[wPFAxPjR:L3G+
MOLM13	M3[0eGN6fG:2b4jpZ4l1gSCjc4PhfS=>		NYfaUm9lPCCmYYnz	MWDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNU2xOOTNiY3XscJMhcGG{Yn;ybY5oKE2OTEGg[pV{cW:wIHflcoUh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPCCmYYnzJIJ6KEOnbHzUbZRmei2JbH:gcJVucW6nc3PlcpQh[XO\|YYmsJGlEPTBiPTCwMlI1OSEQvF2u	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB6MEC2OEc,OjZyOECwOlQ9N2F-
BL21(DE3)	M3jYcGZ2dmO2aX;uJIF{e2G7			NH7iPIdDcW6maX7nJIFn\mmwaYT5JJRwKE5vdHXycYlv[WxiSHnzOk11[WepZXStRnJFPCCkcn;tc4RwdWGrbjCyJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKGOxbYDleIVvfCCHc3Po[ZJq[2irYTDjc4xqKEKOMkGoSGU{MSClZXzsd{BjgSCrc3;0bIVzdWGuIITpeJJifGmxbjDjZYxwemmvZYTyfUwhU2RiPTCwMlA3PSEQvF2u	Mn7VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|Nke1N\|koRjJ4M{[3OVM6RC:jPh?=
BL21(DE3)	NW\5XFhXTnWwY4Tpc44h[XO\|YYm=			NIPMOnVDcW6maX7nJIFn\mmwaYT5JJRwKE5vdHXycYlv[WxiSHnzOk11[WepZXStRnJFPCCkcn;tc4RwdWGrbjCxJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKGOxbYDleIVvfCCHc3Po[ZJq[2irYTDjc4xqKEKOMkGoSGU{MSClZXzsd{BjgSCrc3;0bIVzdWGuIITpeJJifGmxbjDjZYxwemmvZYTyfUwhU2RiPTCwMlA6PSEQvF2u	M2[4UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{[3OVM6Lz5{NkO2O\|U{QTxxYU6=
BL21(DE3)	M1LTb2Z2dmO2aX;uJIF{e2G7			MWjCbY5lcW6pIHHm[olvcXS7IITvJIZ2dGxibHXu[5RpKE5vdHXycYlv[WxiSHnzOk11[WepZXStRnJFOiCkcn;tc4RwdWGrbjCyJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKGOxbYDleIVvfCCHc3Po[ZJq[2irYTDjc4xqKEKOMkGoSGU{MSClZXzsd{BjgSCrc3;0bIVzdWGuIITpeJJifGmxbjDjZYxwemmvZYTyfUwhU2RiPTCwMlEh\|ryPLh?=	M3\2b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{[3OVM6Lz5{NkO2O\|U{QTxxYU6=
BL21(DE3)	NHzRbHVHfW6ldHnvckBie3OjeR?=			NXvSU\|liSmmwZHnu[{Bi\m[rbnn0fUB1dyCodXzsJIxmdme2aDDOMZRmem2rbnHsJGhqezZvdHHn[4VlNUKUREKgZpJwdW:mb33hbY4hOSBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDjc41x\XSnboSgSZNkcGW{aXPobYEh[2:uaTDCUFIyMESHMzmgZ4VtdHNiYomgbZNwfGincn3hcEB1cXS{YYTpc44h[2Gub4LpcYV1enluIFvkJF0hOC5{MzFOwG0v	NXXqVlBERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zOlc2OzlpPkK2N\|Y4PTN7PD;hQi=>
BL21(DE3)-R3-pRARE2	Ml76SpVv[3Srb36gZZN{[Xl?			MofQTY5pcWKrdHnvckBw\iCqdX3hckBJcXNvdHHn[4VlKEKURESgZpJwdW:mb33hbY4hOiCneIDy[ZN{\WRiaX6gSZNkcGW{aXPobYEh[2:uaTDCUFIyMESHMzmtVlMueFKDUlWyJINmdGy\|IHL5JGZTTVRiYYPzZZktKEmFNUCgQUAxNjB\|NjFOwG0v	MmrOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5M{G0PVAoRjJ4N{OxOFkxRC:jPh?=
BL21(DE3)-R3-pRARE2	MnP2SpVv[3Srb36gZZN{[Xl?			NVvLbZg4UW6qaXLpeIlwdiCxZjDoeY1idiCKaYOteIFo\2WmIFLSSFQh[nKxbX;kc41icW5iMTDlfJBz\XO\|ZXSgbY4hTXOlaHXybYNpcWFiY3;sbUBDVDJzKFTFN{kuWjNvcGLBVmUzKGOnbHzzJIJ6KE[URWSgZZN{[XluIFnDOVAhRSByLkCzOkDPxE1w	MkPEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5M{G0PVAoRjJ4N{OxOFkxRC:jPh?=
Rosetta2 DE3	NUfCS41oTnWwY4Tpc44h[XO\|YYm=		MVGzNEBucW6\|	MnniTY5pcWKrdHnvckBw\iCIQV2tcIFj\WynZDDaRmEzPDhiYnnu[Ilv\yC2bzDy[YNwdWKrbnHueEBpfW2jbjDOMZRmem2rbnHsJGhqezZvdHHn[4VlKEKURESgZpJwdW:mb33hbY4hOiBqM{OzJJRwKDR4MDDy[ZNq\HWnczmg[ZhxemW\|c3XkJIlvKFKxc3X0eIEzKESHMzDj[YxteyCjZoTldkA{OCCvaX7zJIJ6KE[ub4Xy[ZNk\W6lZTDwc4xiemm8YYTpc44h[XO\|YYmsJGtqKD1iMD6wNlMh\|ryPLh?=	NWHnc5FRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0OlM1QDdpPkK4OFY{PDh5PD;hQi=>
Rosetta2 DE3	M1y3VWZ2dmO2aX;uJIF{e2G7		NYKwfoE3OzBibXnudy=>	MmnsTY5pcWKrdHnvckBw\iCIQV2tcIFj\WynZDDaRmEzPDhiYnnu[Ilv\yC2bzDy[YNwdWKrbnHueEBpfW2jbjDOMZRmem2rbnHsJGhqezZvdHHn[4VlKEKURESgZpJwdW:mb33hbY4hOSBqNESgeI8hOTZ6IILld4llfWW\|KTDlfJBz\XO\|ZXSgbY4hWm:\|ZYT0ZVIhTEV\|IHPlcIx{KGGodHXyJFMxKG2rboOgZpkhTmyxdYLld4NmdmOnIIDvcIFzcXqjdHnvckBie3OjeTygT4khRSByLkC0OlQh\|ryPLh?=	MkDjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2NkO0PFcoRjJ6NE[zOFg4RC:jPh?=
Rosetta2 DE3	NETj[5FHfW6ldHnvckBie3OjeR?=		M{XuN\|MxKG2rboO=	NV\5OFRiUW6qaXLpeIlwdiCxZjDGRW0udGGkZXzl[EBbSkF{NEigZolv\GmwZzD0c{Bz\WOxbXLpcoFvfCCqdX3hckBPNXSncn3pcoFtKEirc{[teIFo\2WmIFLSSFQh[nKxbX;kc41icW5iMjCoN\|M{KHSxIES2NEBz\XOrZIXld{kh\XiycnXzd4VlKGmwIGLvd4V1fGF{IFTFN{Bk\WyuczDh[pRmeiB\|MDDtbY5{KGK7IF\sc5Vz\XOlZX7j[UBxd2yjcnn6ZZRqd25iYYPzZZktKEmFNUCgQUAxNjB5N{Wg{txONg>?	Mnf1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2NkO0PFcoRjJ6NE[zOFg4RC:jPh?=
MV4-11	NHHBNldIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NYfDcXVHPCCmYYnz	M2PaVWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1XPC1zMTDj[YxteyCjZoTldkA1KGSjeYOgZpkhX1OWLUigZZN{[XluIFnDOVAhRSByLkC5N{DPxE1w	Mm\hQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2NkO0PFcoRjJ6NE[zOFg4RC:jPh?=
Rosetta2 DE3	M3HZSGZ2dmO2aX;uJIF{e2G7		NEfIUXQ{OCCvaX7z	NGLnV2RKdmirYnn0bY9vKG:oIF\BUU1t[WKnbHXkJHpDSTJ2ODDibY5lcW6pIITvJJJm[2:vYnnuZY51KGi3bXHuJG4ufGW{bXnuZYwhUGm\|Nj30ZYdo\WRiQmLEOEBjem:vb3TvcYFqdiBzIDi0OEB1dyBzNkigdoV{cWS3ZYOpJIV5eHKnc4Pl[EBqdiCUb4PleJRiOiCGRUOgZ4VtdHNiYX\0[ZIhOzBibXnud{BjgSCIbH;1doV{[2WwY3WgdI9t[XKrenH0bY9vKGG\|c3H5MEBKSzVyIE2gNE4yPDVizszNMi=>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR4M{S4O{c,Ojh2NkO0PFc9N2F-
MOLM13	MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MVy0JIRigXN?	MYHHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDNU2xOOTNiY3XscJMh[W[2ZYKgOEBl[Xm\|IHL5JHdUXC16IHHzd4F6NCCLQ{WwJF0hOC5{NEGg{txONg>?	M2PydFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NE[zOFg4Lz5{OES2N\|Q5PzxxYU6=
TY82	MV\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NYLkd3pIPzJiaILz	MmTURY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCWWUiyJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCFQ1u4JIF{e2G7LDDJR\|UxKD1iMD6yJO69VS5?	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV6NkexPEc,Ojh3OE[3NVg9N2F-
MM1S	MVHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MVu3NkBpenN?	NHfLXotCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3NNXMh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPDT\|gh[XO\|YYmsJGlEPTBiPTCwMlI{KM7:TT6=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV6NkexPEc,Ojh3OE[3NVg9N2F-
BL21 (DE3)-codon plus-RIL	Mor1SpVv[3Srb36gZZN{[Xl?		M{Ll[FQhcHK\|	NGDDVWRKdmirYnn0bY9vKG:oIFrRNU1HUVSFIHLpcoRqdmdidH:gTIl{Pi22YXfn[YQhSlKGND3CSFEhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iRYPjbIVzcWOqaXGgZ49tcSCETEKxJEhFTTNrLXPv[I9vKHCudYOtVmlNKGOnbHzzJIlv[3WkYYTl[EBqdiCmYYLrJIZweiB2IHjyd{BjgSCobIXvdoV{[2WwY3WgZY5qe2:2cn;wfUBie3OjeTygTWM2OCB;IECuNlYh\|ryPLh?=	M4\lSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NUi2O\|E5Lz5{OEW4OlcyQDxxYU6=
THP1	NGHzOYZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=			MYjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFSKUEGgZ4VtdHNuIFnDOVAhRSByLkK5JO69VS5?	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl\|OUGyNUc,Ojh7M{mxNlE9N2F-
TY82	M1XTbmFvfGmycn;sbYZmemG2aY\lJIF{e2G7			NE\OXo5CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGTZPFIh[2WubIOsJGlEPTBiPTCwMlM6KM7:TT6=	NXzFZmxyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5N\|kyOjFpPkK4PVM6OTJzPD;hQi=>
NALM16	NYfhSmR4S3m2b4TvfIlkcXS7IHHzd4F6		NX7ZN3RUPSCmYYnz	M1vGVWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5CVE1zNjDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZYZ1\XJiNTDkZZl{KGK7IFPlcIxVcXSncj3HcI8h[XO\|YYmsJGVEPTBiPTCwMlI4KM7:TT6=	NHfVboE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG3NFAzPCd-MkmxO\|AxOjR:L3G+
NALM6	M2X1eGN6fG:2b4jpZ4l1gSCjc4PhfS=>		NFW1VGU2KGSjeYO=	MVfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDORWxOPiClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPSCmYYnzJIJ6KEOnbHzUbZRmei2JbH:gZZN{[XluIFXDOVAhRSByLkO5JO69VS5?	MnK0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzN{CwNlQoRjJ7MUewNFI1RC:jPh?=
697	M2XmO2N6fG:2b4jpZ4l1gSCjc4PhfS=>		MWm1JIRigXN?	NFXWcYREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckA3QTdiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDViZHH5d{BjgSCFZXzsWIl1\XJvR3zvJIF{e2G7LDDFR\|UxKD1iMT6xO{DPxE1w	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF5MECyOEc,OjlzN{CwNlQ9N2F-
HD-MB03	MnLFR5l1d3SxeHnjbZR6KGG\|c3H5		NVLZOplkPSCmYYnz	NUTyd3VQS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUERvTVKwN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[W[2ZYKgOUBl[Xm\|IHL5JGNmdGyWaYTldk1IdG9iYYPzZZktKEWFNUCgQUA{NjVizszNMi=>	NVjpNlF1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxO\|AxOjRpPkK5NVcxODJ2PD;hQi=>
A673	M3vPPJFJXFNiYYPzZZk>			M37VbpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy\|	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
DAOY	Mlm3dWhVWyCjc4PhfS=>			NG\QPW1yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiRFHPXUBk\Wyucx?=	M1LVdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Saos-2	M2rLNZFJXFNiYYPzZZk>			NIDsfGZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzz	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
BT-37	MWnxTHRUKGG\|c3H5			M2TVc5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2zO{Bk\Wyucx?=	MkfiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
RD	M2\a[pFJXFNiYYPzZZk>			NYr0ZYtleUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLEJINmdGy\|	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
MG 63 (6-TG R)	M4TYVpFJXFNiYYPzZZk>			MkP0dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE2JIE[zJEg3NVSJIGKpJINmdGy\|	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB1643	NFzsSXlyUFSVIHHzd4F6			MWTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy\|	NYHzNmFwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50	MXrxTHRUKGG\|c3H5			M{mySJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO=	Mmr2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh41	M{HKcZFJXFNiYYPzZZk>			MUPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh2MTDj[Yxtew>?	NEn0Zog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SJ-GBM2	NEPleYlyUFSVIHHzd4F6			MlT3dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO=	NFfNUWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	MkDldWhVWyCjc4PhfS=>			NIK3cJJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=>	NITD[IU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB-EBc1	NWHLOXFieUiWUzDhd5NigQ>?			MX3xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJvRVLjNUBk\Wyucx?=	M17pWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5	MkTOdWhVWyCjc4PhfS=>			NY[zdHgzeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFzBUk02KGOnbHzz	M3X1O\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
TY82	MUPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MVq3NkBpenN?	NITDOGdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGTZPFIh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPDT\|gh[XO\|YYmsJGlEPTBiPTCwMlMxPDNizszNMi=>	NHm3Zmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWyOVQ{PSd-Mkm1NlU1OzV:L3G+
MM1S	MUDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MYK3NkBpenN?	M2HVWmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTV2xV{Bk\WyuczDh[pRmeiB5MjDodpMh[nliQ1PLPEBie3OjeTygTWM2OCB;IECuN\|Q6OiEQvF2u	M4PvRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUK1OFM2Lz5{OUWyOVQ{PTxxYU6=
TY82	M{TV[2Z2dmO2aX;uJIF{e2G7	NEfxOIwxNjJidH:gNUB2VQ>?	M1XPW\|I1KGi{cx?=	MVrJcohq[mm2aX;uJI9nKEKURESgbY4hcHWvYX6gWHk5OiClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ{1OgWNicILveIVqdiCneIDy[ZN{cW:wIHH0JFAvOiC2bzCxJJVOKGGodHXyJFI1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN?	MmXiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3MkW0N\|UoRjJ7NUK1OFM2RC:jPh?=
TY82	MVLGeY5kfGmxbjDhd5NigQ>?	MojZNE4zKHSxIEGgeW0>	NF;JVpAzPCCqcoO=	NFSyfZhKdmirYnn0bY9vKG:oIFLSSFQhcW5iaIXtZY4hXFl6MjDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[y2PeXOgcXJPSSCneIDy[ZN{cW:wIHH0JFAvOiC2bzCxJJVOKGGodHXyJFI1KGi{czDifUBTXC2SQ2KgZY5idHm\|aYO=	NGjNdFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWyOVQ{PSd-Mkm1NlU1OzV:L3G+
TY82 or NCI-H1299	NI\6VVVHfW6ldHnvckBie3OjeR?=	MoL4NE4zKHSxIEGgeW0>	NXnZOoUzOjRiaILz	MWjJcohq[mm2aX;uJI9nKEKURESgbY4hcHWvYX6gWHk5OiCxcjDOR2kuUDF{OUmgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKFCGLVyxJJBzd3SnaX6g[ZhxemW\|c3nvckBifCByLkKgeI8hOSC3TTDh[pRmeiB{NDDodpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	NH20PZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWyOVQ{PSd-Mkm1NlU1OzV:L3G+
TY82 or NCI-H1299	MkXoSpVv[3Srb36gZZN{[Xl?	M1nPUFAvOiC2bzCxJJVO	MYiyOEBpenN?	NWPI[GhIUW6qaXLpeIlwdiCxZjDCVmQ1KGmwIHj1cYFvKFS\OEKgc5IhVkOLLVixNlk6KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDQSE1NOSCvUl7BJIV5eHKnc4Ppc44h[XRiMD6yJJRwKDFidV2gZYZ1\XJiMkSgbJJ{KGK7IGLUMXBEWiCjbnHsfZNqew>?	M4HvN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUK1OFM2Lz5{OUWyOVQ{PTxxYU6=
C4-2B	NWHJTXhISW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MV25OkBpenN?	NXrNSmhOSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDDOE0zSiClZXzsd{Bi\nSncjC5OkBpenNiYomgR4VtdC2WaYTldkBodG9icnXh[4VvfCCkYYPl[EBtfW2rbnXzZ4Vv[2ViYYPzZZk>	M1Hp[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUSxN\|cyLz5{OUW0NVM4OTxxYU6=
22Rv1	MknKRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NIHJOFc6PiCqcoO=	NFO1VpFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIEKyVpYyKGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDD[YxtNVSrdHXyJIdtdyC{ZXHn[Y51KGKjc3XkJIx2dWmwZYPj[Y5k\SCjc4PhfS=>	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV2MUO3NUc,Ojl3NEGzO\|E9N2F-
LNCAP	NHLu[\|FCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MlW2PVYhcHK\|	MmjnRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCOTlPBVEBk\WyuczDh[pRmeiB7NjDodpMh[nliQ3XscE1VcXSncjDncI8hemWjZ3XueEBj[XOnZDDseY1qdmW\|Y3XuZ4Uh[XO\|YYm=	MnK1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3NEGzO\|EoRjJ7NUSxN\|cyRC:jPh?=
HL60	M3XqcmN6fG:2b4jpZ4l1gSCjc4PhfS=>			MW\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIJ6KE2WUzDhd5NigSxiSVO1NEA:KDBwMUKg{txONg>?	NWf0OnpVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm2OVcxQTlpPkK5OlU4ODl7PD;hQi=>
Raji	MnziSpVv[3Srb36gZZN{[Xl?			NYrEOJhtUW6qaXLpeIlwdiCxZjDCVmQ1NUKGMTDpckBpfW2jbjDSZYpqKGOnbHzzJIF{e2W\|c3XkJIF{KGSxd37y[Yd2dGG2aX;uJI9nKE2\QzDn[Y5mKGW6cILld5Nqd25iYomgVGNTKG2ndHjv[EwhUUN3MDC9JFAvOTN{IN88UU4>	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTZ3N{C5PUc,Ojl4NUewPVk9N2F-
LNCAP	MlHORY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?			M2S1XGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTF7DRXAh[2WubIOsJGlEPTBiPTCwMlM2PjVizszNMi=>	MnGwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5NUi1NVgoRjJ7N{W4OVE5RC:jPh?=
MV411	NFzmPYZEgXSxdH;4bYNqfHliYYPzZZk>		M4XzNlczKGi{cx?=	MYPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNWlQyOSClZXzsd{Bi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhUUN3MDC9JFAvQCEQvF2u	M1XQSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMk[4O\|AzLz5\|MEK2PFcxOjxxYU6=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Growth inhibition assay	Cell viability ; PubMed: 26840085 Oncotarget A., B. and C. Dose response curves of MPNST-derived cell lines treated with three bromodomain inhibitors: JQ1, OTX015 and I-BET-762.	26840085

体内研究

I-BET-762保护防止脂多糖诱导的内毒素休克和细菌诱导的脓毒病。LPS注射后1.5小时，单剂量I-BET处理，可治愈小鼠。I-BET每日两次注射，持续2天，保护小鼠免于脓毒症引起的死亡。^[1]早期I-BET-762处理实验性自身免疫性脑脊髓炎（EAE）小鼠模型，抑制Th1分化的2D2 T细胞诱发神经性炎症的能力。^[2]

激酶实验：^[1]	- 合并荧光共振能量转移（FRET）滴定: 在有四乙酰化的组蛋白H4肽（200 nM）存在时，在50 mM HEPES pH7.5, 50 mM NaCl, 0.5 mM CHAPS中进行对BRD2 (200 nM), BRD3 (100 nM) 和 BRD4 (50 nM)的I-BET滴定。平衡1小时后，在含0.05% (v/v) BSA 和 400 mM KF的实验缓冲液中加入2nM 铕穴状化合物标记的链霉亲和素和10 nM XL-665标记的anti-6His 抗体，使用FRET检测溴区蛋白：肽相互作用。使用Envision酶标仪（激发菠菜320 nm，发射波长615 nm和665 nm）对实验板进行读数。
细胞实验：^[2]	- 合并 Cell lines: CD4⁺ T 细胞 Concentrations: ~500 nM Incubation Time: 60-72 小时 Method: 从10到12周的小鼠淋巴结和脾中分离CD4⁺ T细胞，在指定细胞因子存在时，使用与板结合的anti-CD3和anti-CD28抗体活化。在最初激活的60-72小时，包含I-BET-762化合物。在T细胞培养和扩张的5天过程中，化合物稀释到初始浓度的12倍。 (Only for Reference)
动物实验：^[1]	- 合并 Animal Models: 小鼠 Dosages: 30 mg/kg Administration: 静脉注射 (Only for Reference)

参考文献

溶解度 (25°C)

体外	DMSO	84 mg/mL (198.15 mM)
	Ethanol	42 mg/mL warmed (99.07 mM)
	Water	Insoluble

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Molibresib (I-BET-762) SDF

分子量	423.9
化学式	C₂₂H₂₂ClN₅O₂
CAS号	1260907-17-2
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	GSK525762, GSK525762A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03266159	Withdrawn	Drug: GSK525762 Besylate tablets\|Drug: Trametinib tablets	Solid Tumours	GlaxoSmithKline	November 27 2017	Phase 2
NCT02964507	Active not recruiting	Drug: GSK525762\|Drug: Placebo\|Drug: Fulvestrant	Neoplasms	GlaxoSmithKline	February 2 2017	Phase 1
NCT01943851	Completed	Drug: GSK525762	Neoplasms	GlaxoSmithKline	May 14 2014	Phase 2
NCT01587703	Completed	Drug: GSK525762	Carcinoma Midline	GlaxoSmithKline	March 28 2012	Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

选择性强的BET抑制剂

PFI-1 (PF-6405761) : BRD4-selective, IC50=0.22 μM.
用于临床的BET抑制剂

RVX-208 ^New : Phase II for Dyslipidemia.

研究领域

产品类型

定制您的化合物库

Molibresib (I-BET-762)

客户使用Selleck生产的Molibresib (I-BET-762)发表文献21篇：

产品安全说明书

Epigenetic Reader Domain抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Molibresib (I-BET-762) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-09-06)

技术支持

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features